Rescue trials
are among the most demanding in clinical research, requiring rapid onboarding, seamless transitions, and immediate impact. Precision was brought in to rescue a global Phase 3 study comparing XRd (study drug + lenalidomide + dexamethasone) versus Rd (lenalidomide + dexamethasone) in patients with relapsed multiple myeloma.
Study Type |
Phase 3 |
Therapeutic Area |
Oncology |
Indication |
Relapsed Multiple Myeloma |
Geography |
20 countries |
Sites |
>150 sites, >790 patients |
Precision’s Role |
Rescue trial management, global coordination, site engagement, and data quality oversight |
The study had already opened but planned to expand to 155 sites across 20 countries and enroll a target of 780. However, operational inconsistencies and site dissatisfaction threatened data quality and timelines.
Precision’s oncology team implemented a cohesive global strategy to stabilize and accelerate the trial. Key actions included:
This structured approach ensured that all stakeholders—from sites to sponsor—were aligned and empowered to execute.
Following Precision’s intervention, the trial saw immediate improvements:
These results validated Precision’s ability to not only recover a struggling study but elevate its performance beyond expectations.
Rescue trials require clarity, speed, and precision. Early alignment, transparent communication, and experienced teams are essential to turning around complex global studies.
Precision’s rescue of this multiple myeloma trial exemplifies the power of strategic planning, experienced personnel, and global coordination. The trial was stabilized, accelerated, and completed ahead of schedule—preserving scientific integrity and sponsor confidence.